10:25am
FII View: A positive macro-and-policy-fuelled India was the most preferred
emerging market across all financial centres in Europe at the end of 2014, says
Deutsche Bank in a research report. But now global as well as emerging markets
investors are looking at a tactical reallocation of aggressively overweight
positions towards other EM's like China, Russia and Brazil, the report says.
Deutsche
Bank met as many as 34 investors last week across key financial centers in
Europe.
The
brokerage house further says: "Many global investors we met – who were
first time investors into India, through the rally last year, are currently
focused on European equity markets, following improving economic data and QE in
Europe."
Focusing
on India, the report says, the ongoing tactical correction is a healthy
consolidation and investors waiting on the sidelines should use this as an
opportunity to realign their portfolios.
Deutsche
Bank maintains its year-end Sensex target of 33,000.
10:00am
Market Check
The
market continued to see marginal gains in morning trade led by banking & financials,
FMCG and select oil stocks. The Sensex rose 71.09 points to 27747.13 and the
Nifty climbed 12.20 points to 8389.95.
The
BSE Midcap and Smallcap indices gained 0.3 percent and 0.6 percent,
respectively. More than two shares advanced for every share declining on the
Bombay Stock Exchange.
Sun Pharma rebounded with 2 percent gains after a 9 percent fall in previous session. JP Morgan has maintained overweight rating on the stock with a target price of Rs 1030. "Large correction was driven by supply from Daiichi’s stake sale (down 19 percent over last 2 weeks including correction yesterday)," said the brokerage, adding he will use the weakness as a buying opportunity.
Sun Pharma rebounded with 2 percent gains after a 9 percent fall in previous session. JP Morgan has maintained overweight rating on the stock with a target price of Rs 1030. "Large correction was driven by supply from Daiichi’s stake sale (down 19 percent over last 2 weeks including correction yesterday)," said the brokerage, adding he will use the weakness as a buying opportunity.
He
believes the base Sun Pharma business (ex-Ranbaxy) can grow at more than 15
percent over medium term and sees significant upside from integration /
turnaround of Ranbaxy acquisition, manufacturing related synergies.
HUL
also rallied 2 percent followed by ICICI Bank, ITC, Reliance Industries, Axis
Bank, M&M, HDFC Bank, HDFC, Dr Reddy's Labs and Hero Motocorp with 0.3-1.3
percent.
No comments:
Post a Comment